Make an enquiry
Refer a patient
Patient Portal
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
2024-06-20T09:22:04.664Z

ProstACT-Global

ProstACT-Global
Prostate cancer

177Lu-DOTA-rosopatamab With Best Standard of Care (SoC) for the Second Line of Treatment for Metastatic Castrate-resistant Prostate Cancer, Which Expresses PSMA (PROSTACT)

177Lu-DOTA-rosopatamab With Best Standard of Care (SoC) for the Second Line of Treatment for Metastatic Castrate-resistant Prostate Cancer, Which Expresses PSMA (PROSTACT)

Trial overview

Clinical Area

Theranostics

Disease / Condition

Prostate cancer

Study Phase

III

Trial registration

Number: NCT04876651

https://clinicaltrials.gov/study/NCT04876651

GenesisCare Location(s)

GenesisCare Murdoch (Oncology) 

GenesisCare Murdoch (Oncology)  :::
GenesisCare Location(s)

Avril Singh

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.